- Home
- PAGP vs NAMS Comparison
PAGP vs NAMS Comparison
Compare PAGP & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PAGP | NAMS |
|---|---|---|
| Founded | 2013 | 2019 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Natural Gas Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 3.5B |
| IPO Year | 2013 | N/A |
Fundamental Metrics
Financial Performance| Metric | PAGP | NAMS |
|---|---|---|
| Price | $23.36 | $29.05 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 8 |
| Target Price | $21.63 | ★ $46.75 |
| AVG Volume (30 Days) | ★ 1.7M | 829.1K |
| Earning Date | 05-08-2026 | 05-07-2026 |
| Dividend Yield | ★ 7.16% | N/A |
| EPS Growth | ★ 370.00 | N/A |
| EPS | ★ 0.27 | N/A |
| Revenue | ★ $44,262,000,000.00 | N/A |
| Revenue This Year | $12.42 | $25.64 |
| Revenue Next Year | N/A | $530.85 |
| P/E Ratio | $86.39 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $16.61 | $14.06 |
| 52 Week High | $24.00 | $42.00 |
Technical Indicators
Market Signals| Indicator | PAGP | NAMS |
|---|---|---|
| Relative Strength Index (RSI) | 64.25 | 39.71 |
| Support Level | $18.53 | $23.48 |
| Resistance Level | $24.00 | $37.43 |
| Average True Range (ATR) | 0.38 | 1.70 |
| MACD | -0.08 | -0.23 |
| Stochastic Oscillator | 63.11 | 13.64 |
Price Performance
Historical ComparisonAbout PAGP Plains GP Holdings L.P. Units representing Limited Partner Interests
Plains GP Holdings LP provides transportation, storage, processing, fractionation, and marketing services for crude oil, refined products, natural gas liquids, liquefied petroleum gas, and related products. The group manages its operations through two operating segments: Crude Oil and NGL.
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.